Author’s response to reviews

Title: A case of leukocytoclastic vasculitis with purpura and renal failure induced by the anti-EGFR antibody panitumumab

1 Hitomi Kamo, Eiji Shinozaki2, Takanobu Sugase1, Nobuyuki Mizunuma2, Shoji Taniguchi1, Takashi Gotoh1, Keisyo Chin2, Tomoaki Tanaka1, Kazumi Koga1, and Kensei Yamaguchi 1)

1) Surgery, Koga General Hospital, Miyazaki, Japan
2) Gastrointestinal Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

Corresponding author details
Hitomi Kamo, Department of Surgery, Koga General Hospital, Miyazaki, Japan
mizunuman12@gmail.com eiji.shinozaki@gmail.com

Authors:

Hitomi Kamo (mizunuman12@gmail.com)
Eiji Shinozaki (eiji.shinozaki@gmail.com)
Takanobu Sugase (takasuga@kgh.or.jp)
Shoji Taniguchi (taniguchi@kgh.or.jp)
Takashi Gotoh (gotochan@kgh.or.jp)
Keisyo Chin (kchin@jfcr.or.jp)
Tomoaki Tanaka (tomoaki-tanaka@kgh.or.jp)
Nobuyuki Mizunuma (mizunuman9@gmail.com)
Kazumi Koga (koga@kgh.or.jp)
Kensei Yamaguchi (kensei.yamaguchi@jfcr.or.jp)

Version: 1 Date: 20 Aug 2018

Author’s response to reviews:

Dear Dr. Rakesh Garg, Dr. Sohail Abdul Salim, and Dr. Otabek Yangibaev

It is honor that my paper is acceptable.

I thank you for your thoughtful indication and warm comments.

I reviewed my paper and amended the following points.
1. This case demonstrates a case of vasculitis. Renal biopsy had fibrocellular crescents with no Immune complex depositon and +blood on microscopy and Cresenteric Glomerulonephritis cannot be ruled out.

Not reported in this case reported is whether there was any acanthocytes on urine analysis or serum magnesium level which would have given more insight.

* I added the urine analysis in the manuscript at page 4, line 14. Acanthocytes were seen on uroscopy.

* I abbreviate the data of Mg at page 5, line 16.

2. However, one relevant aspect is missing that is RAS and BRAF V600E status?

* RAS status was wild. BRAF V600E is not covered in Japanese national license even in today. So BRAF V600E was not measured in this case.

I inserted RAS status in the manuscript at page 4, line 3.

3. There are few minor mistakes in the text that may require proofreading. For example:

On the first paragraph, 4th line of the case presentation: "(tube 1 plus tube 2)".

Also sequence of figures (for example: figure 5, 6, 7) does not correspond to the text of the manuscript.

* As your pointed out, “tub1 plus tub2” had been deleted. These words are for Japanese guideline. And I revised number of figures to the correct numbers as follows, (figure 5→4, figure6→5, figure7→6).

4. And also, while describing your case and specifically pathological picture/grading which system did you use?
Figure 3 is skin biopsy was observed at x200, and kidney necropsy was observed at x800 on light microscopy.

5. According to which protocol panitumumab infusion was administered?

* I treated with bi-weekly single panitumumab therapy based on 20020408 study protocol (Phase 3 Metastatic Colorectal Cancer Study).

* I added the schedule of panitumumab at page 4, line 5.

6. References that authors kindly provided may not be entirely accurate, and require amending them accordingly.

* Thank you for your identification, I corrected references and added some references.

Again, thank you for your viewing, Here I have enclosed my revised paper.

Sincerely yours,